Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic(tktx) -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (3)	4/27/1998 3:25:00 PM
From: R. Dolan	Read Replies (1) \| Respond to of 122

It doesn't appear many are here on this board, but this release came out same day the lawsuit release did. The stock shot up to $35 from $29 or so on the news, but as of today was back down around $28. Doesn't exactly "compute" given the nature of the news releases? I have no info to pass along except I've been following this since November when a someone told a relative it might be a good one. Rick --------------------------- RESEARCH ALERT - Transkaryotic <TKTX.O> upgraded NEW YORK, April 16 (Reuters) - Morgan Stanley Dean Witter said it raised its rating on Transkaryotic Therapies Inc. to strong buy from outperform. Morgan analyst Douglas Lind said that Transkaryotic and a marketing partner have prevailed in a patent-infringement lawsuit filed by Amgen Inc. <AMGN.O>. Transkaryotic stock was off 18 percent so far this year, apparently related to uncertainty about the litigation. The company's fundamentals are gaining momentum. The price target is $51. Transkaryotic was up 6 at 34-1/2 in morning trading. 11:08 04-16-98